{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:49:52Z","timestamp":1789505392706,"version":"build-2803163510"},"reference-count":12,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"<jats:sec>\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Patients with refractory hypercholesterolemia who do not achieve their guideline-defined low-density lipoprotein cholesterol (LDL-C) thresholds despite treatment with maximally tolerated combinations of lipid-lowering therapies (LLTs) have an increased risk of atherosclerotic cardiovascular disease (ASCVD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate longer-term efficacy and safety of evinacumab in patients with refractory hypercholesterolemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This randomized clinical trial included a 2-week screening period followed by a 16-week double-blind treatment period (DBTP) for subcutaneous regimens (evinacumab, 450 mg, once weekly [QW]; evinacumab, 300 mg, QW; evinacumab, 300 mg, every 2 weeks; or placebo QW) or a 24-week DBTP for intravenous regimens (evinacumab, 15 mg\/kg, every 4 weeks [Q4W]; evinacumab, 5 mg\/kg, Q4W; or placebo Q4W); a 48-week open-label treatment period (OLTP) for intravenous treatment only; and a 24-week follow-up period. Patients from 85 sites across 20 countries were recruited for the study; patients with primary hypercholesterolemia (defined as heterozygous familial hypercholesterolemia or established clinical ASCVD without familial hypercholesterolemia) who entered the 48-week OLTP were included. In addition, the patients\u2019 hypercholesterolemia was refractory to maximally tolerated LLTs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>All patients entering the OLTP received evinacumab, 15 mg\/kg, intravenously Q4W.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Efficacy outcomes included change in LDL-C level and other lipid\/lipoprotein parameters from baseline to week 72 (end of the OLTP). Safety outcomes included assessment of treatment-emergent adverse events (TEAEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 96 patients (mean [SD] age, 54.4 [11.3] years; 52 female [54.2%]) entered the OLTP, of whom 88 (91.7%) completed the OLTP. Mean (SD) baseline LDL-C level was 145.9 (55.2) mg\/dL. At week 72, evinacumab, 15 mg\/kg, reduced mean (SD) LDL-C level from baseline by 45.5% (28.7%) in the overall cohort. Evinacumab, 15 mg\/kg, reduced mean (SD) apolipoprotein B (38.0% [22.1%]), non\u2013high density lipoprotein cholesterol (48.4% [23.2%]), total cholesterol (42.6% [17.5%]), and median (IQR) fasting triglyceride (57.2% [65.4%-44.4%]) levels at week 72 from baseline in the overall cohort. TEAEs occurred in 78 of 96 patients (81.3%). Serious TEAEs occurred in 9 of 96 patients (9.4%); all were considered unrelated to study treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In patients with refractory hypercholesterolemia, evinacumab provided sustained reductions in LDL-C level and was generally well tolerated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov Identifier:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03175367\">NCT03175367<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamacardio.2023.2921","type":"journal-article","created":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T11:03:39Z","timestamp":1694603019000},"page":"1070","source":"Crossref","is-referenced-by-count":35,"title":["Longer-Term Efficacy and Safety of Evinacumab in Patients With Refractory Hypercholesterolemia"],"prefix":"10.1001","volume":"8","author":[{"given":"Robert S.","family":"Rosenson","sequence":"first","affiliation":[{"name":"Metabolism and Lipids Unit, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley J.","family":"Burgess","sequence":"additional","affiliation":[{"name":"TREAD Research Centre, Cardiology Unit, Department of Internal Medicine, Stellenbosch University and Tygerberg Hospital, Parow, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph F.","family":"Ebenbichler","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth J.","family":"Baum","sequence":"additional","affiliation":[{"name":"Excel Medical Clinical Trials and Department of Integrated Medical Sciences, Charles E Schmidt College of Medicine, Florida Atlantic University, Boca Raton"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik S. G.","family":"Stroes","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shazia","family":"Ali","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagwa","family":"Khilla","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"McGinniss","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gaudet","sequence":"additional","affiliation":[{"name":"Clinical Lipidology and Rare Lipid Disorders Unit, Department of Medicine, Universit\u00e9 de Montr\u00e9al Community Gene Medicine Center, and ECOGENE-21 Clinical and Translational Research Center, Chicoutimi, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Pordy","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc, Tarrytown, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"25","key":"hbr230019r1","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 Study.","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"32","key":"hbr230019r2","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"issue":"24","key":"hbr230019r3","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines.","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"hbr230019r4","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013225","article-title":"Diagnosis and treatment of heterozygous familial hypercholesterolemia.","volume":"8","author":"McGowan","year":"2019","journal-title":"J Am Heart Assoc"},{"issue":"22","key":"hbr230019r5","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","article-title":"The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association.","volume":"132","author":"Gidding","year":"2015","journal-title":"Circulation"},{"issue":"45","key":"hbr230019r6","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"hbr230019r7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.atherosclerosis.2020.07.018","article-title":"Very high-risk familial hypercholesterolemia patients in real life: the remaining gap in achieving the current LDL-C targets despite the use of PCSK9 inhibitors.","volume":"309","author":"Rallidis","year":"2020","journal-title":"Atherosclerosis"},{"issue":"17","key":"hbr230019r8","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1093\/eurjpc\/zwaa097","article-title":"Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study.","volume":"28","author":"Gaudet","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"14","key":"hbr230019r9","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee.","volume":"80","author":"Lloyd-Jones","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"hbr230019r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2021.100060","article-title":"Existing and emerging therapies for the treatment of familial hypercholesterolemia.","volume":"62","author":"Rosenson","year":"2021","journal-title":"J Lipid Res"},{"issue":"24","key":"hbr230019r11","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","article-title":"Evinacumab in patients with refractory hypercholesterolemia.","volume":"383","author":"Rosenson","year":"2020","journal-title":"N Engl J Med"},{"key":"hbr230019r12","unstructured":"Regeneron Pharmaceuticals Inc. EVKEEZA (evinacumab-dgnb) injection, for intravenous use. Accessed April 9, 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/761181s000lbl.pdf"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2809517\/jamacardiology_rosenson_2023_br_230019_1698258730.94848.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T11:06:10Z","timestamp":1699441570000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2809517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":12,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2023.2921","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,1]]}}}